In Brief: Rorer's Nasacort AQ Nasal Spray
This article was originally published in The Tan Sheet
Executive Summary
Rorer's Nasacort AQ Nasal Spray: Rhone-Poulenc Rorer submits sNDA for approval of product's benefits to "children as young as four," RPR announced Oct. 22. Submission contains results from two double-blind, placebo-controlled trials involving 538 children with seasonal or perennial allergic rhinitis. At doses of 110 mcg or 220 mcg once daily, Nasacort AQ was found to effect "statistically significant reductions of allergic rhinitis symptoms." Pharyngitis, fever, rhinitis, and flu symptoms were the most commonly reported adverse events. Should Nasacort switch to OTC, Ciba would gain rights to its marketing per the companies' December 1994 agreement ("The Tan Sheet" Jan. 2, 1995, p. 4)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning